BioCryst Pharmaceuticals, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2012.
[More]
Reportlinker.com announces that a new market research report is available in its catalogue: Global Ophthalmic Instrumentation Industry
[More]
Rheumatoid arthritis patients can develop gout, say researchers who believe changes in treatment and obesity may explain why the comorbidity is now occurring.
[More]
A vasopressin V2-receptor blocker slows the increase in total kidney volume and decline in kidney function in patients with autosomal dominant polycystic kidney disease, report US researchers.
[More]
BioCryst Pharmaceuticals, Inc. today announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza. The difference between peramivir and control groups for the primary endpoint was small and the recalculated sample size was greater than the predefined futility boundary of 320 subjects. Based on this information, the independent data monitoring committee (DMC) recommended that the study be terminated for futility.
[More]
BioCryst Pharmaceuticals, Inc. today announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.S. Food and Drug Administration (FDA).
[More]
More rheumatologists are embracing musculoskeletal ultrasound (MSUS) to diagnose and manage rheumatic diseases. In response, the American College of Rheumatology (ACR) assembled a task force to investigate and determine best practices for use of MSUS in rheumatology practice. The resulting scenario-based recommendations, which aim to help clinicians understand when it is reasonable to integrate MSUS into their rheumatology practices, now appear online in Arthritis Care & Research.
[More]
Savient Pharmaceuticals, Inc. and its wholly owned subsidiary, Savient Pharma Ireland Limited, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has completed its scientific assessment and has issued a positive opinion recommending approval of a marketing authorization in the European Union for KRYSTEXXA for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.
[More]
Gout is one of the most common forms of inflammatory arthritis, affecting nearly 4% of adult Americans. Newly approved guidelines that educate patients in effective methods to prevent gout attacks and provide physicians with recommended therapies for long-term management of this painful disease are published in Arthritis Care & Research, a peer-reviewed journal of the American College of Rheumatology (ACR).
[More]
A new study found that patients with gout who consumed cherries over a two-day period showed a 35% lower risk of gout attacks compared to those who did not eat the fruit.
[More]
The University of Alabama at Birmingham is establishing a Center of Research Translation to improve the health of an increasing number of patients with gout and hyperuricemia.
[More]
Pfizer Inc. announced today that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-α-2a) in the first-line treatment of patients with advanced renal cell carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population.
[More]
Patients across the spectrum of rheumatic diseases, not just those with rheumatoid arthritis, have a significantly increased prevalence of cardiovascular risk factors compared with the general population, the results of a Dutch study indicate.
[More]
Regeneron Pharmaceuticals, Inc. today announced financial and operating results for the second quarter of 2012 and provided an update on development programs.
[More]
BioCryst Pharmaceuticals, Inc. today announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208) added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.
[More]
Gout is a significant and independent risk factor for the development of myocardial infarction, even in younger patients and those with no other cardiovascular risk factors, researchers report in Rheumatology.
[More]
Gout has been described by the Daily Mail as something, “usually associated with port-swilling, over-fed elderly men of the 19th century”. (1) Recent research carried out at the Boston University School of Medicine, however, has found that the incidence of gout in the US is on the rise. (2) Thus, the condition is clearly not something that only affects this stereotype.
[More]
Savient Pharmaceuticals, Inc. today announced a new publication showing that adult patients with refractory chronic gout (RCG) treated bi-weekly with KRYSTEXXA- (pegloticase) experienced statistically significant and clinically meaningful improvements in health-related quality of life (HRQOL), pain and physical function.
[More]
Researchers from Boston University School of Medicine (BUSM) have found that the incidence of gout and hyperuricemia (high uric acid levels) in the U.S. has risen significantly over the last 20 years and is associated with major medical disorders like hypertension and chronic kidney disease.
[More]
A new study by researchers at St. Michael's Hospital suggests that fructose may not be as bad for us as previously thought and that it may even provide some benefit.
[More]